Projects

Norrsken Mind funded the first Swedish clinical trial using a psilocybin-assisted therapy protocol. At Karolinska Institutet, the study investigates the effects of psilocybin on symptoms of depression and synaptic density.

Learn more

Norrsken Mind, through our predecessor organisation Osmond Foundation, funded an epidemiological research program by Karolinska Institutet researchers Otto Simonsson, PhD and Walter Osika, MD PhD, investigating the link between the use of classic psychedelics and different somatic disorders

Learn more

Norrsken Mind sponsored the Nordic Psychedelic Science Conference (NPSC) 2022 which took place in Oslo, Norway, on the 19th and 20th of May 2022. The following is a post-conference report from project manager Anna Høifødt.

Learn more

The research project aims to investigate adolescent and young adult use and experience of psychedelics in two different and natural settings through survey, longitudinal observation, and in-depth interview, in Sweden (where use is discouraged) and Brazil (in a population where use is encouraged). The project is led by Emma Claesdotter Knutsson, Associate Professor at the unit for Clinical Research on Externalizing and Developmental psychopathology at Lund University, and David Sjöström, child and adolescent psychiatrist resident and PhD student at Lund University.

Learn more

Norrsken Mind supports researchers at Karolinska Institutet to investigate the cognitive and neurobiological changes associated with psilocybin-assisted therapy, which may offer insights into the neurobiology of major depressive disorder and the therapeutic mechanisms of psilocybin. The project is led by Predrag Petrovic, Associate Professor at the Department of Clinical Neuroscience at Karolinska Institutet.

Learn more

Norrsken Mind is co-funding a planned study at Østfold Hospital to evaluate MDMA-assisted psychotherapy as a treatment for young adults (aged 18-25) with major depressive disorder. The study is led by Ole Andreassen, Professor at University of Oslo, in collaboration with Eva Henje, Professor at Umeå University, Mark Berthold-Losleben, consultant psychiatrist at Østfold Hospital and Associate Professor at Norwegian University of Science & Technology, and Tor-Morten Kvam, consultant psychiatrist at Østfold Hospital and doctoral student at University of Oslo. 

Learn more

Norrsken Mind has previously co-funded an epidemiological research program at Karolinska Institutet led by Otto Simonsson, PhD, and Walter Osika, MD and Associate professor in clinical neuroscience, investigating the link between psychedelic use and physical health. In a new project, the research team will investigate the genetic and environmental contributions to psychiatric risks and benefits of psychedelic use in vulnerable populations.

Learn more

Norrsken Mind is funding a randomized controlled trial at Lund University to evaluate the effectiveness, safety and tolerability of two 25 mg doses of psilocybin, in comparison to standard treatment, for young adults with severe anorexia nervosa. Potential mechanisms of action will be investigated through self-reports, neurobiological assessments, and neuroimaging techniques. The study will involve 40 participants and is led by Pouya Movahed Rad, Senior researcher, at Lund University.

Learn more

Norrsken Mind is funding research focused on the psychotherapeutic component of psilocybin treatments. This project includes analyzing data from two clinical trials, involving more than 120 patients, and seeks to better understand the therapeutic framework needed for safe and effective administration of psilocybin for depression. The project is led by Maria Beckman, Senior researcher at Karolinska Institutet, in collaboration with Johan Lundberg, Adjunct Professor at Karolinska Institutet. 

Learn more

Norrsken Mind is co-funding a planned randomized, double-blind, placebo-controlled trial at the University of Copenhagen (UCPH) to evaluate the short- and long-term effects of psilocybin for depression when administered within a psychotherapeutic framework versus a medical support model. The study will involve 120 patients and is led by Dea Siggaard Stenbæk, Associate Professor at UCPH, in collaboration with Maria Beckman, Senior researcher at Karolinska Institutet. 

Learn more

Norrsken Mind funded a research project to produce a comprehensive report on reimbursement pathways for psychedelic treatments in Europe. The project was led by Floris Wolswijk, founder of Blossom (a psychedelic science and insight platform), and Martin Gisby, independent healthcare consultant with over 15 years of experience. 

Learn more

Norrsken Mind is funding the Independent Psychedelic Evidence Assessment Working Group (IPEA-WG) to develop new, rigorous and multidisciplinary standards for evaluating evidence related to psychedelic therapies. The project is led by Eduardo Schenberg, MSc, PhD (Faculty of Medicine, University of Lisbon), with co-chairs Franklin King, MD (Massachusetts General Hospital) and Marion Haberkamp, MD (German Federal Institute for Drugs and Medical Devices, BfArM).

Learn more

Norrsken Mind is a founding member and supporter of the Psychedelic Access and Research European Alliance (PAREA), a non-profit, multidisciplinary partnership advancing the safe, ethical, and equitable integration of psychedelic-assisted care into European healthcare.

Learn more

Norrsken Mind is supporting the Open Psilocybin Study (OPS), an innovative multi-session experimental study at Leiden University and the Centre for Human Drug Research (CHDR), designed to investigate how low-to-medium doses of psilocybin affect the brain, body, and self-perception compared to placebo. The study will recruit 40 healthy participants and is led by Associate Professor Michiel van Elk, in collaboration with researchers at the CHDR.

Learn more

Drug Science will convene a panel of clinical experts, alongside patient representatives, to evaluate treatments for treatment-resistant depression (TRD). Using a multi-criteria decision analysis (MCDA) framework, the project will assess both therapeutic benefits and safety across a wide range of interventions, including psychedelic treatments. The findings are intended to inform clinical practice, regulatory decision-making, and policy development.

Learn more

Norrsken Mind is supporting Heal Ukraine Trauma (HUT) in expanding a training program that prepares psychotherapists, psychologists, and psychiatrists in Ukraine to provide group Ketamine-Assisted Psychotherapy (KAP) for military veterans. HUT is an initiative of Heal Traumas International, Inc., a U.S. non-profit organization founded in 2022 to build sustainable, evidence-based mental health solutions in conflict-affected settings.

Learn more

Norrsken Mind was a main partner of the Borealis Psychedelic Science Summit 2025, together with Nostromo Foundation. The summit was held in Stockholm on September 26–27. The event brought together over 300 participants from 21 countries for Sweden’s second national psychedelic science conference. Organized by the Swedish Network for Psychedelic Science (NPV), the summit explored the latest advances in psychedelic research and their translation into clinical and policy contexts.

Learn more